Tuesday, March 15, 2016 12:11:54 PM
$TPIV ~ TapImmune, Inc. due diligence report
$TPIV recent news/filings
## source: finance.yahoo.com
$TPIV charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$TPIV company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/TPIV/company-info
Ticker: $TPIV
OTC Market Place: OTCQB
CIK code: 0001094038
Company name: TapImmune, Inc.
Company website: http://www.tapimmune.com
Incorporated In: NV, USA
Business Description: Cancer and viral disease immunotherapy products R&D company
$TPIV share structure
## source: otcmarkets.com
Market Value: $39,999,014 a/o Mar 14, 2016
Shares Outstanding: 64,618,762 a/o Nov 16, 2015
Float: 26,744,609 a/o May 01, 2015
Authorized Shares: 500,000,000 a/o May 01, 2015
Par Value: Not Available
$TPIV extra dd links
Company name: TapImmune, Inc.
Company website: http://www.tapimmune.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TPIV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TPIV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TPIV+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TPIV/news - http://finance.yahoo.com/q/h?s=TPIV+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TPIV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TPIV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TPIV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TPIV
DTCC (dtcc.com): http://search2.dtcc.com/?q=TapImmune%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=TapImmune%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=TapImmune%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.tapimmune.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.tapimmune.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.tapimmune.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TPIV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001094038&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TPIV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TPIV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TPIV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TPIV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TPIV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TPIV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TPIV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TPIV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TPIV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TPIV+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TPIV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TPIV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TPIV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TPIV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TPIV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TPIV/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TPIV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TPIV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TPIV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TPIV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TPIV
$TPIV DD Notes ~ http://www.ddnotesmaker.com/TPIV
Recent MRKR News
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors • GlobeNewswire Inc. • 08/28/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:47:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:39:13 PM
- Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/14/2024 08:30:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:12:59 AM
- Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma • GlobeNewswire Inc. • 08/12/2024 11:00:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:05:47 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM